Focus
The Predictive Safety Testing Consortium
- Focus issue:
- May 2010 Volume 28, No 5
Editorial
Focus on The Predictive Safety Testing Consortium
Biomarkers on a roll - p431
doi:10.1038/nbt0510-431
A consortium of industry, nonprofit institutions and regulators outlines a rolling biomarker qualification process, providing the first clear path for translation of such markers from discovery to preclinical and clinical practice.
Abstract - Biomarkers on a roll | Full Text - Biomarkers on a roll | PDF (128 KB) - Biomarkers on a roll
Foreword
Focus on The Predictive Safety Testing Consortium
Research at the interface of industry, academia and regulatory science - pp432 - 433
William B Mattes, Elizabeth Gribble Walker, Eric Abadie, Frank D Sistare, Jacky Vonderscher, Janet Woodcock & Raymond L Woosley
doi:10.1038/nbt0510-432
Full Text - Research at the interface of industry, academia and regulatory science | PDF (91 KB) - Research at the interface of industry, academia and regulatory science
Glossary
Focus on The Predictive Safety Testing Consortium
Glossary - pp434 - 435
doi:10.1038/nbt0510-434
Opinion and Comment
Commentary
Focus on The Predictive Safety Testing Consortium
Next-generation biomarkers for detecting kidney toxicity - pp436 - 440
Joseph V Bonventre, Vishal S Vaidya, Robert Schmouder, Peter Feig & Frank Dieterle
doi:10.1038/nbt0510-436
There is a paucity of biomarkers that reliably detect nephrotoxicity. The Predictive Safety Testing Consortium (PSTC) faced several challenges in identifying novel safety biomarkers in the renal setting.
Abstract - Next-generation biomarkers for detecting kidney toxicity | Full Text - Next-generation biomarkers for detecting kidney toxicity | PDF (391 KB) - Next-generation biomarkers for detecting kidney toxicity
Focus on The Predictive Safety Testing Consortium
Evolution of biomarker qualification at the health authorities - pp441 - 443
Federico Goodsaid & Marisa Papaluca
doi:10.1038/nbt0510-441
By streamlining the qualification process for biomarkers, coordinated protocols recently implemented at the different regulatory agencies can facilitate progress and provide impetus to novel biomarker discovery and validation.
Abstract - Evolution of biomarker qualification at the health authorities | Full Text - Evolution of biomarker qualification at the health authorities | PDF (314 KB) - Evolution of biomarker qualification at the health authorities
News and Views
Focus on The Predictive Safety Testing Consortium
A roadmap for biomarker qualification - pp444 - 445
David G Warnock & Carl C Peck
doi:10.1038/nbt0510-444
A collaborative effort between pharmaceutical companies, regulatory agencies and academia to qualify biomarkers for kidney toxicity provides a model for investigating and identifying reliable safety markers for preclinical applications.
Full Text - A roadmap for biomarker qualification | PDF (137 KB) - A roadmap for biomarker qualification
Research
Perspectives
Focus on The Predictive Safety Testing Consortium
Towards consensus practices to qualify safety biomarkers for use in early drug development - pp446 - 454
Frank D Sistare, Frank Dieterle, Sean Troth, Daniel J Holder, David Gerhold, Dina Andrews-Cleavenger, William Baer, Graham Betton, Denise Bounous, Kevin Carl, Nathaniel Collins, Peter Goering, Federico Goodsaid, Yi-Zhong Gu, Valerie Guilpin, Ernie Harpur, Alita Hassan, David Jacobson-Kram, Peter Kasper, David Laurie, Beatriz Silva Lima, Romaldas Maciulaitis, William Mattes, Gérard Maurer, Leslie Ann Obert, Josef Ozer, Marisa Papaluca-Amati, Jonathan A Phillips, Mark Pinches, Matthew J Schipper, Karol L Thompson, Spiros Vamvakas, Jean-Marc Vidal, Jacky Vonderscher, Elizabeth Walker, Craig Webb & Yan Yu
doi:10.1038/nbt.1634
Abstract - Towards consensus practices to qualify safety biomarkers for use in early drug development | Full Text - Towards consensus practices to qualify safety biomarkers for use in early drug development | PDF (307 KB) - Towards consensus practices to qualify safety biomarkers for use in early drug development | Supplementary information
Focus on The Predictive Safety Testing Consortium
Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium - pp455 - 462
Frank Dieterle, Frank Sistare, Federico Goodsaid, Marisa Papaluca, Josef S Ozer, Craig P Webb, William Baer, Anthony Senagore, Matthew J Schipper, Jacky Vonderscher, Stefan Sultana, David L Gerhold, Jonathan A Phillips, Gérard Maurer, Kevin Carl, David Laurie, Ernie Harpur, Manisha Sonee, Daniela Ennulat, Dan Holder, Dina Andrews-Cleavenger, Yi-Zhong Gu, Karol L Thompson, Peter L Goering, Jean-Marc Vidal, Eric Abadie, Romaldas Maciulaitis, David Jacobson-Kram, Albert F Defelice, Elizabeth A Hausner, Melanie Blank, Aliza Thompson, Patricia Harlow, Douglas Throckmorton, Shen Xiao, Nancy Xu, William Taylor, Spiros Vamvakas, Bruno Flamion, Beatriz Silva Lima, Peter Kasper, Markku Pasanen, Krishna Prasad, Sean Troth, Denise Bounous, Denise Robinson-Gravatt, Graham Betton, Myrtle A Davis, Jackie Akunda, James Eric McDuffie, Laura Suter, Leslie Obert, Magalie Guffroy, Mark Pinches, Supriya Jayadev, Eric A Blomme, Sven A Beushausen, Valérie G Barlow, Nathaniel Collins, Jeff Waring, David Honor, Sandra Snook, Jinhe Lee, Phil Rossi, Elizabeth Walker & William Mattes
doi:10.1038/nbt.1625
Abstract - Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium | Full Text - Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium | PDF (293 KB) - Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium
Articles
Focus on The Predictive Safety Testing Consortium
Urinary clusterin, cystatin C, β2-microglobulin and total protein as markers to detect drug-induced kidney injury - pp463 - 469
Frank Dieterle, Elias Perentes, André Cordier, Daniel R Roth, Pablo Verdes, Olivier Grenet, Serafino Pantano, Pierre Moulin, Daniel Wahl, Andreas Mahl, Peter End, Frank Staedtler, François Legay, Kevin Carl, David Laurie, Salah-Dine Chibout, Jacky Vonderscher & Gérard Maurer
doi:10.1038/nbt.1622
Current biomarkers for detecting kidney damage, such as serum creatinine (SCr) and blood urea nitrogen (BUN), lack the sensitivity needed for use in drug development. Urinary clusterin outperforms SCr and BUN in detecting proximal tubular injury, and urinary total protein, cystatin C and β2-microglobulin each outperform either SCr or BUN in detecting glomerular injury.
Abstract - Urinary clusterin, cystatin C, [beta]2-microglobulin and total protein as markers to detect drug-induced kidney injury | Full Text - Urinary clusterin, cystatin C, β2-microglobulin and total protein as markers to detect drug-induced kidney injury | PDF (1,328 KB) - Urinary clusterin, cystatin C, β2-microglobulin and total protein as markers to detect drug-induced kidney injury | Supplementary information
Focus on The Predictive Safety Testing Consortium
Urinary biomarkers trefoil factor 3 and albumin enable early detection of kidney tubular injury - pp470 - 477
Yan Yu, Hong Jin, Daniel Holder, Josef S Ozer, Stephanie Villarreal, Paul Shughrue, Shu Shi, David J Figueroa, Holly Clouse, Ming Su, Nagaraja Muniappa, Sean P Troth, Wendy Bailey, John Seng, Amy G Aslamkhan, Douglas Thudium, Frank D Sistare & David L Gerhold
doi:10.1038/nbt.1624
Exposure of rats to kidney toxicants reduces levels of urinary trefoil factor 3 (TFF3) and increases levels of urinary albumin. Whereas urinary albumin outperforms either serum creatinine (SCr) or blood urea nitrogen (BUN) for detecting kidney tubule damage, urinary TFF3 abundance complements the capacity of combined SCr and BUN levels to detect renal injury.
Abstract - Urinary biomarkers trefoil factor 3 and albumin enable early detection of kidney tubular injury | Full Text - Urinary biomarkers trefoil factor 3 and albumin enable early detection of kidney tubular injury | PDF (1,393 KB) - Urinary biomarkers trefoil factor 3 and albumin enable early detection of kidney tubular injury | Supplementary information
Focus on The Predictive Safety Testing Consortium
Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies - pp478 - 485
Vishal S Vaidya, Josef S Ozer, Frank Dieterle, Fitz B Collings, Victoria Ramirez, Sean Troth, Nagaraja Muniappa, Douglas Thudium, David Gerhold, Daniel J Holder, Norma A Bobadilla, Estelle Marrer, Elias Perentes, André Cordier, Jacky Vonderscher, Gérard Maurer, Peter L Goering, Frank D Sistare & Joseph V Bonventre
doi:10.1038/nbt.1623
Urinary kidney injury-1 (Kim-1) outperforms serum creatinine, blood urea nitrogen and urinary N-acetyl-β-D-glucosaminidase in detecting kidney damage induced in rats by a range of nephrotoxicants. Earlier detection of renal injury, enabled by monitoring levels of urinary Kim-1, should enable elimination of nephrotoxic candidates sooner in the drug development pipeline.
Abstract - Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies | Full Text - Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies | PDF (1,024 KB) - Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies | Supplementary information
Focus on The Predictive Safety Testing Consortium
A panel of urinary biomarkers to monitor reversibility of renal injury and a serum marker with improved potential to assess renal function - pp486 - 494
Josef S Ozer, Frank Dieterle, Sean Troth, Elias Perentes, André Cordier, Pablo Verdes, Frank Staedtler, Andreas Mahl, Olivier Grenet, Daniel R Roth, Daniel Wahl, François Legay, Daniel Holder, Zoltan Erdos, Katerina Vlasakova, Hong Jin, Yan Yu, Nagaraja Muniappa, Tom Forest, Holly K Clouse, Spencer Reynolds, Wendy J Bailey, Douglas T Thudium, Michael J Topper, Thomas R Skopek, Joseph F Sina, Warren E Glaab, Jacky Vonderscher, Gérard Maurer, Salah-Dine Chibout, Frank D Sistare & David L Gerhold
doi:10.1038/nbt.1627
A panel of urinary biomarkers enables the progression of renal injury and subsequent repair and recovery to be monitored after exposure of rats to either carbapenem A or gentamicin. The authors complement this study by demonstrating that serum cystatin C is more sensitive and specific than serum creatinine and blood urea nitrogen in monitoring generalized renal function after exposure to nephrotoxicants.
Abstract - A panel of urinary biomarkers to monitor reversibility of renal injury and a serum marker with improved potential to assess renal function | Full Text - A panel of urinary biomarkers to monitor reversibility of renal injury and a serum marker with improved potential to assess renal function | PDF (1,137 KB) - A panel of urinary biomarkers to monitor reversibility of renal injury and a serum marker with improved potential to assess renal function | Supplementary information